Federated Wireless secured the return of founding investor Allied Minds for a $13.7m extension that will expand wireless communications services forged on Virginia Tech research.

The mobile frequency technology provider added $13.7m to an SBA Communications and American Tower-backed round now sized at $64.7m.

Repeatome drug developer Rome Therapeutics is based on intellectual property from Massachusetts General Hospital and Icahn School of Medicine at Mount Sinai.

Otsuka Pharmaceuticals's McQuade Center for Strategic Research and Development backed the psilocybin-based mental health drug developer through the round.

Repeatome drug developer Rome Therapeutics was incubated within GV, which took part in the series A round along with fellow corporate unit Partners Innovation Fund.

The digital life insurer has revealed it closed a series B round in February that included Sammons Financial to increase its total funding to more than $67m.

GV, AbbVie Ventures and NS Investment have contributed to a series B round for the oncology drug developer, which has now raised a total of $103m.

The HLB-led group owns nearly half of vaccine product developer Immunomic Therapeutics following a $61.3m commitment this year.

Partners Innovation Fund joined Syncona to provide $20m for the neurological disease drug developer's series A round, which is sized at up to $77m.

SwanBio, based on research at Harvard Medical School, has secured a $20m extension to bring its series A round to $45m so far, with commitments to increase it to $77m.